CO23 Validating the Results of a Matching Adjusted Indirect Comparison (MAIC) in MET Exon 14 (METex14) Skipping Non-Small Cell Lung Cancer (NSCLC)

Tepotinib is approved in multiple countries for METex14 skipping NSCLC based on the Phase II VISION study (NCT02864992). As this study did not contain a control arm, real-world data (RWD) from five pooled sources in patients with METex14 skipping NSCLC were used to estimate the comparative effectiveness of tepotinib against pembrolizumab. However, uncertainty exists in the comparisons due to the non-randomized nature of RWD. This study aimed to confirm the findings of the RWD analysis using published clinical trial data.